Mirum Pharmaceuticals, Inc.
A pharmaceutical company focused on rare diseases, it markets three FDA-approved medicines: Livmarli for the severe itching of certain inherited liver conditions, Ctexli for cerebrotendinous xanthomatosis, and Cholbam for bile acid disorders. It was founded in 2018 by a team that revived its lead drug after pharmaceutical giant Shire set it aside, and its name comes from Latin, meaning "wonder" or "marvel."
Granted 105.0K · Sold 71.0K
Granted 53.1K · Sold 16.5K
Granted 15.7K · Sold 12.3K
Granted 13.3K · Sold 7.3K
Granted 4.0K
Granted 4.0K
Granted 4.0K
Granted 8.7K · Sold 7.3K
Granted 10.0K · Sold 10.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Peetz ChristopherCHIEF EXECUTIVE OFFICER, Director · 10 transactions | +17.7% | 409.2K | 105.0K | — | 71.0K |
| Radovich PeterPRESIDENT AND COO · 5 transactions | +177.2% | 57.3K | 53.1K | — | 16.5K |
| Bjerkholt EricCHIEF FINANCIAL OFFICER · 6 transactions | +7.9% | 47.2K | 15.7K | — | 12.3K |
| Quan JoanneCHIEF MEDICAL OFFICER · 2 transactions | +47.2% | 18.9K | 13.3K | — | 7.3K |
| Fischer LaurentDirector · 1 transaction | +58.9% | 10.7K | 4.0K | — | — |
| Cardon LonDirector · 1 transaction | +69.7% | 9.7K | 4.0K | — | — |
| Walbert Timothy PDirector · 1 transaction | +69.7% | 9.7K | 4.0K | — | — |
| Howe JolandaSVP, GLOBAL CONTROLLER · 4 transactions | +29.6% | 5.8K | 8.7K | — | 7.3K |
| Ramasastry SairaDirector · 8 transactions | — | 0 | 10.0K | — | 10.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -124.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.